Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

<
<<
Previous
Page 1 of 3330
Next
>>
>
1 to 25 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
184B5	NM	Basal	Nilotinib	ABL	nRTK	1.6	uM	12566.17	0.9380	0.9145	1.4648
600MPE	HR+	Luminal	Nilotinib	ABL	nRTK	0.32	uM	12224.145	1.0747	1.1536	0.9737
184A1	NM	Basal	Nilotinib	ABL	nRTK	8	uM	12509.17	0.9098	0.8689	1.3955
184B5	NM	Basal	Nilotinib	ABL	nRTK	0.32	uM	12566.17	0.9589	0.9436	1.4648
600MPE	HR+	Luminal	Nilotinib	ABL	nRTK	0.000512	uM	12224.145	1.0393	1.0807	0.9737
600MPE	HR+	Luminal	Nilotinib	ABL	nRTK	0.064	uM	12224.145	1.0114	1.0233	0.9737
184A1	NM	Basal	Nilotinib	ABL	nRTK	0.0128	uM	12509.17	0.9642	0.9484	1.3955
184A1	NM	Basal	Nilotinib	ABL	nRTK	1.6	uM	12509.17	0.8925	0.8434	1.3955
184B5	NM	Basal	Nilotinib	ABL	nRTK	0.000512	uM	12566.17	1.0026	1.0035	1.4648
184B5	NM	Basal	Nilotinib	ABL	nRTK	0.064	uM	12566.17	0.9827	0.9763	1.4648
184B5	NM	Basal	Nilotinib	ABL	nRTK	40	uM	12566.17	0.9504	0.9318	1.4648
184B5	NM	Basal	Nilotinib	ABL	nRTK	200	uM	12566.17	0.9436	0.9223	1.4648
600MPE	HR+	Luminal	Nilotinib	ABL	nRTK	0.00256	uM	12224.145	0.9747	0.9481	0.9737
600MPE	HR+	Luminal	Nilotinib	ABL	nRTK	0.0128	uM	12224.145	1.0414	1.0850	0.9737
184A1	NM	Basal	Nilotinib	ABL	nRTK	0.000512	uM	12509.17	1.0051	1.0074	1.3955
184A1	NM	Basal	Nilotinib	ABL	nRTK	0.00256	uM	12509.17	1.0256	1.0365	1.3955
184A1	NM	Basal	Nilotinib	ABL	nRTK	0.064	uM	12509.17	0.9781	0.9686	1.3955
184A1	NM	Basal	Nilotinib	ABL	nRTK	0.32	uM	12509.17	0.9479	0.9248	1.3955
184A1	NM	Basal	Nilotinib	ABL	nRTK	40	uM	12509.17	0.8807	0.8260	1.3955
184A1	NM	Basal	Nilotinib	ABL	nRTK	200	uM	12509.17	0.9381	0.9104	1.3955
184B5	NM	Basal	Nilotinib	ABL	nRTK	0.00256	uM	12566.17	0.9796	0.9720	1.4648
184B5	NM	Basal	Nilotinib	ABL	nRTK	0.0128	uM	12566.17	0.9920	0.9890	1.4648
184B5	NM	Basal	Nilotinib	ABL	nRTK	8	uM	12566.17	0.9553	0.9386	1.4648
600MPE	HR+	Luminal	Nilotinib	ABL	nRTK	8	uM	12224.145	1.0259	1.0533	0.9737
600MPE	HR+	Luminal	Nilotinib	ABL	nRTK	1.6	uM	12224.145	1.0373	1.0766	0.9737

<
<<
Previous
Page 1 of 3330
Next
>>
>
1 to 25 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)